Beam Therapeutics Inc (BEAM) Stock is more thoughtful than you think

JP Morgan raised the price target for the Beam Therapeutics Inc (NASDAQ:BEAM) stock from “a Neutral” to “an Overweight”. The rating was released on January 29, 2024, according to finviz. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $30. The stock was downgraded by […]

Beam Therapeutics Inc (BEAM) Stock: Pessimism is a stepping stone to opportunity

JP Morgan raised the price target for the Beam Therapeutics Inc (NASDAQ:BEAM) stock from “a Neutral” to “an Overweight”. The rating was released on January 29, 2024, according to finviz. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $30. The stock was downgraded by […]

Beam Therapeutics Inc (BEAM) Stock to return to profitability in the near future

JP Morgan raised the price target for the Beam Therapeutics Inc (NASDAQ:BEAM) stock from “a Neutral” to “an Overweight”. The rating was released on January 29, 2024, according to finviz. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $30. The stock was downgraded by […]

Top-line Growth is Likely to Be Driven by Beam Therapeutics Inc (BEAM) Stock

JP Morgan raised the price target for the Beam Therapeutics Inc (NASDAQ:BEAM) stock from “a Neutral” to “an Overweight”. The rating was released on January 29, 2024, according to finviz. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $30. The stock was downgraded by […]

Beam Therapeutics Inc (NASDAQ:BEAM) Stock upgraded by JP Morgan

JP Morgan raised the price target for the Beam Therapeutics Inc (NASDAQ:BEAM) stock from “a Neutral” to “an Overweight”. The rating was released on January 29, 2024, according to finviz. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $30. The stock was downgraded by […]

Why Beam Therapeutics Inc (NASDAQ:BEAM) Stock Jumped 43.66% in Last Month?

JP Morgan raised the price target for the Beam Therapeutics Inc (NASDAQ:BEAM) stock from “a Neutral” to “an Overweight”. The rating was released on January 29, 2024, according to finviz. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $30. The stock was downgraded by […]

Yummy or too sour? Beam Therapeutics Inc (BEAM) Stock

JP Morgan raised the price target for the Beam Therapeutics Inc (NASDAQ:BEAM) stock from “a Neutral” to “an Overweight”. The rating was released on January 29, 2024, according to finviz. Historical Earnings Surprises and Revenue Forecasts Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings […]

A Tale from the Dusty Corner: Beam Therapeutics Inc (BEAM) Stock

JP Morgan raised the price target for the Beam Therapeutics Inc (NASDAQ:BEAM) stock from “a Neutral” to “an Overweight”. The rating was released on January 29, 2024, according to finviz. Historical Earnings Surprises and Revenue Forecasts Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings […]